Quick Summary
- Needham shifts stance to Buy from Hold on ARM, establishing a $200 price objective
- The chipmaker introduced its debut in-house AGI CPU processor at the “Arm Everywhere” conference
- Meta Platforms becomes inaugural customer for ARM’s proprietary chip technology
- Jefferies increases price objective to $210, projecting $15B revenue opportunity through FY2031
- Latest quarterly results exceeded expectations with $0.43 EPS versus $0.41 forecast and 26.3% revenue growth
After maintaining a neutral position for nearly thirty months, Needham elevated Arm Holdings to a Buy rating on Wednesday, establishing a twelve-month price objective of $200.
Arm Holdings plc American Depositary Shares, ARM
The investment firm highlighted ARM’s strategic initiatives in the semiconductor industry — implementing higher royalty structures, moving into subsystem offerings, and now manufacturing proprietary processors. According to Needham, these approaches are beginning to deliver results.
ARM has achieved 26.45% revenue expansion over the trailing twelve-month period. Nineteen Wall Street analysts have increased their earnings projections for the forthcoming period.
A central element of the upgraded outlook involves ARM’s venture into chip manufacturing through its partnership with Meta Platforms. Meta has committed as the inaugural commercial client for ARM’s proprietary processor, the AGI CPU, providing the technology with significant market validation immediately.
The AGI CPU made its official debut during ARM’s “Arm Everywhere” conference. Following the announcement, Jefferies elevated its price objective to $210 from $170, emphasizing the processor’s capacity to deliver $15 billion in incremental revenue by the 2031 fiscal year.
Barclays confirmed its Overweight assessment and increased its target to $200 from $165. The investment bank emphasized the power efficiency characteristics of the AGI CPU architecture as a critical competitive edge for artificial intelligence applications.
BofA Securities adjusted its target upward to $155 from $140 while maintaining a Neutral stance. Morgan Stanley preserved its Overweight rating with a $135 objective, acknowledging ARM’s innovative dual-chiplet processor architecture designed for cloud-based AI deployments.
Wall Street Consensus View
Current analyst consensus registers as Moderate Buy, with a mean price objective of $168.17. This assessment derives from 19 Buy recommendations, 6 Hold positions, and 1 Sell rating.
ARM’s 50-day moving average registers at $120.72, while the 200-day average sits at $134.17. The equity trades within a 52-week range spanning $80.00 to $183.16 and maintains approximately $165.95 billion in market capitalization.
The company carries a P/E ratio of 209. InvestingPro analysis indicates the equity appears overvalued compared to its Fair Value assessment.
During its latest reporting period, ARM delivered EPS of $0.43, surpassing the $0.41 analyst estimate. Revenue totaled $1.24 billion, representing 26.3% year-over-year growth and marginally exceeding the $1.23 billion consensus expectation.
Fourth Quarter Outlook
ARM projected Q4 FY2026 guidance ranging from $0.54 to $0.62 EPS. The analyst community collectively anticipates full-year EPS of $0.90.
Needham emphasized the emergence of agentic artificial intelligence and the expanding importance of CPUs within AI datacenter infrastructure as sustained positive catalysts for ARM’s market position.
The AGI CPU targets agentic AI applications, incorporating a multi-core, energy-optimized architecture. Industry observers indicate the processor will require comprehensive software and hardware ecosystem development to challenge established competitors such as Nvidia, Intel, and AMD.
Susquehanna upgraded ARM from Neutral to Positive in January, setting a $150 price target. Mizuho reduced its objective from $190 to $160 in February while preserving an Outperform rating.
Institutional investors control 7.53% of outstanding shares.





